Pharma channel feed

J&J's Acte­lion buy­out pays off again with ap­proval of Op­syn­vi in pul­monary ar­te­r­i­al hy­per­ten­sion

Last year
FDA+

Es­pe­ri­on eyes new com­mer­cial push for cho­les­terol-low­er­ing drugs af­ter big FDA la­bel ex­pan­sion

Last year
FDA+

No­vo to buy mid-stage heart fail­ure biotech Car­dior for up to $1.1B

Last year
Startups
Deals

Lead House spon­sor of WuXi-linked bill to leave Con­gress ear­ly

Last year
People
China

FDA to delete 'Y­ou are not a horse' post and oth­ers in iver­mectin case set­tle­ment

Last year
FDA+
Marketing

Leqem­bi au­tho­riza­tion in EU is de­layed for pro­ce­dur­al is­sues

Last year

Seagen’s for­mer com­mer­cial chief joins the board at health­care agency minds + as­sem­bly

Last year
People
Marketing

GSK to part ways with 'most' Bel­lus Health em­ploy­ees a year af­ter $2B buy

Last year
People

Novo's week­ly in­sulin se­cures CHMP thumbs-up as FDA de­ci­sion looms

Last year

FDA ap­proves Ital­far­ma­co’s drug Du­vyzat for Duchenne mus­cu­lar dy­s­tro­phy

Last year
FDA+

Glob­al AIDS pro­gram re­vived in gov­ern­ment spend­ing pack­age as oth­er health rid­ers fall off

Last year
FDA+

Di­a­betes and weight loss drug ad­ver­tis­ing tops $1B on strength of GLP-1 brand spend­ing

Last year
Marketing

Ken­tucky is the fourth state to al­low in­sur­ers to re­quire biosim­i­lar pre­scrip­tions be­fore brand­ed ver­sions

Last year
FDA+

Mer­ck re­ports an­oth­er fail­ure for Keytru­da-Lyn­parza com­bo in non-small cell lung can­cer

Last year
R&D

VML Health part­ners on new key opin­ion leader man­age­ment for bio­phar­mas

Last year
Marketing

GSK joins Boehringer and As­traZeneca in cap­ping out-of-pock­et costs for in­halers

Last year

Medicare and Med­ic­aid open cov­er­age of an­ti-obe­si­ty drugs for heart pa­tients

Last year

Sen­ate opens probe in­to how high-risk re­search pos­es na­tion­al se­cu­ri­ty threats

Last year
China

Bay­er's re­struc­tur­ing hits phar­ma lead­er­ship, shift­ing about half of ex­ecs off top team

Last year
People

FDA ap­proves Idor­sia’s high blood pres­sure drug for pa­tients who need oth­er op­tions

Last year
FDA+

The Op­di­vo-Yer­voy com­bo from Bris­tol My­ers is work­ing to­ward ap­proval in first-line liv­er can­cer

Last year
R&D

As­traZeneca de­buts Air­supra DTC cam­paign along with a first-ever tele­health op­tion

Last year
Marketing

Lab­corp ex­pands Alzheimer’s blood tests for doc­tors and drug­mak­ers

Last year
R&D

Or­chard sets US price tag for rare dis­ease gene ther­a­py Len­meldy at $4.25M

Last year
Cell/Gene Tx
First page Previous page 63646566676869 Next page Last page
A service from the Financial Times